Jay Venkatesan - 27 Dec 2021 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role
President and Chief Executive Officer and Director, Director
Signature
/s/ Jennifer J. Rhodes, as attorney-in fact for Jay. R. Venkatesan
Issuer symbol
ELTX
Transactions as of
27 Dec 2021
Net transactions value
+$730,373
Form type
4
Filing time
29 Dec 2021, 15:08:05 UTC
Previous filing
22 Dec 2021
Next filing
04 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELTX Common Stock Purchase $170,519 +66,907 +4.9% $2.55 1,428,920 27 Dec 2021 Direct F1
transaction ELTX Common Stock Purchase $559,854 +210,337 +15% $2.66 1,639,257 28 Dec 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.55 inclusive.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.75 inclusive.

Remarks:

President and Chief Executive Officer and Director